more

Ophthotech Corporation (ISEE)

(Delayed Data from NSDQ)

$1.43 USD

+0.08 (5.93%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.43 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study

by Zacks Equity Research Published on November 30,2021

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential

by Zacks Equity Research Published on November 29,2021

Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.

Takeda (TAK) CMV Infection Drug Livtencity Gets FDA Approval

by Zacks Equity Research Published on November 25,2021

The FDA grants approval to the new drug application seeking approval for Takeda's (TAK) maribavir for treating post-transplant cytomegalovirus infection.

pharmaceuticals

Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension

by Zacks Equity Research Published on November 24,2021

Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA to reviewnew data submission.

biotechs

BioMarin's (BMRN) Dwarfism Drug Gets FDA's Nod, Stock Up

by Zacks Equity Research Published on November 22,2021

Biomarin Pharmaceuticals's (BMRN) Voxzogo is the first medicine in the United States to be approved to treat achondroplasia, the most common form of dwarfism.

pharmaceuticals

New Strong Sell Stocks for August 18th

by Zacks Equity Research Published on August 18,2021

CYTK, GEVO, ISEE, MCFE, and NOMD have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2021.

Implied Volatility Surging for IVERIC bio (ISEE) Stock Options

by Zacks Equity Research Published on August 18,2021

Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.

ISEEPositive Net Change

IVERIC bio (ISEE) Enters Overbought Territory

by Zacks Equity Research Published on July 14,2021

IVERIC bio (ISEE) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

ISEEPositive Net Change

medical

Do Options Traders Know Something About IVERIC bio (ISEE) Stock We Don't?

by Zacks Equity Research Published on July 12,2021

Investors need to pay close attention to IVERIC bio (ISEE) stock based on the movements in the options market lately.

ISEEPositive Net Change

New Strong Sell Stocks for April 26th

by Zacks Equity Research Published on April 26,2021

ARR, GMDA, ISEE, LMB, and LIQT have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2021

New Strong Sell Stocks for April 21st

by Zacks Equity Research Published on April 21,2021

EXTN, PSXP, ISEE, OR, and QIWI have been added to the Zacks Rank #5 (Strong Sell) List on April 21, 2021

New Strong Sell Stocks for April 6th

by Zacks Equity Research Published on April 06,2021

JOBS, BUD, EURN, ISEE, and KL have been added to the Zacks Rank #5 (Strong Sell) List on April 6, 2021

New Strong Sell Stocks for March 11th

by Zacks Equity Research Published on March 11,2021

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

J&J (JNJ) Acquires Rights for Hemera Biosciences' Gene Therapy

by Zacks Equity Research Published on December 03,2020

Johnson & Johnson's (JNJ) Janssen acquires rights to investigational gene therapy, HMR59, for the treatment of geographic atrophy.

IVERIC bio (ISEE) Catches Eye: Stock Jumps 6.8%

by Zacks Equity Research Published on October 16,2020

IVERIC bio (ISEE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

medical

Moving Average Crossover Alert: IVERIC bio

by Zacks Equity Research Published on July 03,2020

IVERIC bio, Inc. (ISEE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.